NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Acute Myeloid Leukemia Real World Treatment Patterns

WithdrawnN/A

Sponsor: Pfizer

Conditions: Leukemia, Myeloid, Acute

Interventions: azacitidine, venetoclax, glasdegib

Among patients with a diagnosis of AML who received non-intensive chemotherapy: * Describe patient demographic and clinical characteristics * Describe treatment patterns * Describe effectiveness outcomes * Evaluate tumor response

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse (CRN) review of provider documentation of AML diagnosis in the medical record.
2. Receipt of non-intensive therapy at any point during first line therapy following initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of the following agents, alone or in combination with any other agent:

   1. AZA
   2. GLAS
   3. VEN
3. Age ≥18 years at initial diagnosis of AML.

Exclusion Criteria:

Patients meeting any of the following criteria will not be included in the study:

1\. Record of 1 or more of the following confounding diagnoses at any point before or after AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.